^
Association details:
Biomarker:KDR elevation
Cancer:Skin Cancer
Drug:pazopanib (Multi-tyrosine kinase inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

A multicenter phase II study of pazopanib in patients with unresectable or recurrent dermatofibrosarcoma protuberans (DFSP).

Published date:
05/16/2018
Excerpt:
...phase II study of pazopanib in patients…received pazo 800 mg qd. High plasma level of soluble VEGFR2 was associated with tumor response (p = 0.01)….suggest that pazo is a therapeutic option in DFSP....dermatofibrosarcoma protuberans (DFSP)...
DOI:
10.1200/JCO.2018.36.15_suppl.11557
Trial ID: